Creatine HCl Supplementation in Sarcopenia: A Randomized Controlled Study

Impact of 12-Week Creatine HCl Supplementation on Body Composition, Functional Muscle and Brain Performance, Blood Biomarkers, and Tissue Creatine Levels in Older Adults With Sarcopenia

The CONCRET-SARCOPA trial is a 12-week, double-blind, randomized controlled study designed to evaluate the efficacy of creatine HCl supplementation in older adults with sarcopenia. The trial investigates whether daily creatine HCl improves body composition, enhances functional muscle and cognitive performance, and favorably alters key blood biomarkers associated with muscle health and metabolic status. Additionally, the study assesses changes in tissue creatine levels using non-invasive and biochemical methods to clarify mechanistic responses to supplementation. Findings from this trial will provide critical evidence on the therapeutic potential of creatine HCl as a targeted nutritional strategy for managing sarcopenia in the geriatric population.

Inclusion Criteria:

• Age > 60 years
• Low muscle strength by handgrip (SDOC criteria for sarcopenia): < 35.5 kg in men and < 20 kg in women
• Sign free and informed consent
• Demonstrate interest, conditions and availability to participate

Exclusion Criteria:

• Patients undergoing interventional treatment for sarcopenia
• Physical amputation
• Cognitive impairment (MSSE < 25)
• Unwillingness to return for follow-up analysis
• Participation in other clinical trials